RAND Corporation, Arlington, Virginia (Sherry), Boston (Dick), and Pittsburgh (Stein); Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor (Nguyen); O'Neill School of Public and Environmental Affairs, Indiana University, Bloomington (Bradford, Simon).
Psychiatr Serv. 2023 Jan 1;74(1):24-30. doi: 10.1176/appi.ps.20220070. Epub 2022 Jun 30.
Because individuals with a history of depression who are receiving opioids are at higher risk for adverse events, the authors examined whether antidepressant treatment reduces risk for overdose and self-harm among individuals with a history of depression who receive opioids.
Commercial insurance claims of individuals with a history of depression receiving opioids from 2007 to 2017 were used to quantify the association between antidepressant fills and adverse events among individuals after initiation of opioid treatment; the authors accounted for selection into treatment and used discrete-time, proportional hazards survival models.
Among 283,374 adults with a history of depression treatment, 8,203 experienced 47,486 adverse events from 2007 to 2017 in the 12 months after initiation of opioid treatment. Approximately half (N=144,052, 50.8%) filled an antidepressant prescription at least once in the 12 months after the opioid episode began. Individuals receiving antidepressants for at least 6 weeks had a reduced risk for any adverse event (adjusted odds ratio [AOR]=0.79, 95% confidence interval [CI]=0.65-0.97) as well as a reduced risk for opioid overdoses (AOR=0.78, 95% CI=0.64-0.96), overdoses from nonopioid controlled substances (AOR=0.76, 95% CI=0.62-0.94), overdoses from other substances (AOR=0.79, 95% CI=0.65-0.97), and other self-harm events (AOR=0.82, 95% CI=0.67-1.00).
Individuals with a history of depression who received opioid analgesics had a significantly lower risk for overdose and self-harm after they had been taking antidepressants for at least 6 weeks. Universal screening for mood disorders among individuals receiving opioids, and promptly providing evidence-based depression treatment when appropriate, may reduce adverse events.
由于有抑郁病史的个体在接受阿片类药物时发生不良事件的风险较高,作者研究了抗抑郁治疗是否会降低有抑郁病史且正在接受阿片类药物治疗的个体发生药物过量和自伤的风险。
使用 2007 年至 2017 年有抑郁病史且正在接受阿片类药物治疗的个体的商业保险理赔数据,量化了个体开始接受阿片类药物治疗后抗抑郁药物治疗与不良事件之间的关联;作者考虑了治疗选择,并使用离散时间、比例风险生存模型。
在 283374 名有抑郁治疗史的成年人中,有 8203 人在开始接受阿片类药物治疗后的 12 个月内经历了 47486 起不良事件。在阿片类药物发作后的 12 个月内,大约有一半(N=144052,50.8%)至少开了一次抗抑郁药物处方。至少连续服用 6 周抗抑郁药物的个体发生任何不良事件的风险降低(调整后的优势比[OR]=0.79,95%置信区间[CI]=0.65-0.97),药物过量的风险降低(OR=0.78,95%CI=0.64-0.96),非阿片类受控物质药物过量的风险降低(OR=0.76,95%CI=0.62-0.94),其他物质药物过量的风险降低(OR=0.79,95%CI=0.65-0.97),以及其他自伤事件的风险降低(OR=0.82,95%CI=0.67-1.00)。
有抑郁病史且正在接受阿片类镇痛药治疗的个体在开始至少连续服用 6 周抗抑郁药物后,药物过量和自伤的风险显著降低。对接受阿片类药物治疗的个体进行情绪障碍的普遍筛查,并在适当情况下及时提供基于证据的抑郁症治疗,可能会降低不良事件的发生风险。